John Collison — Dave Ricks on GLP-1s, AI drug discovery & Lilly Direct | 5 minutes

AI and Advanced Computing in Pharma

• 💡 Eli Lilly is building an on-premises supercomputer with Nvidia specifically for proprietary drug discovery models, aiming to discover molecules not found in nature.
• 🧠 This initiative is considered the biggest biologically focused supercomputer built by a pharma company, combining machine-driven chemistry with human judgment.
• 🔬 The current understanding of human biology is estimated at only 10-15%, with machines expected to improve as richer biological datasets emerge.
• 💬 Modern Large Language Models (LLMs) like Claude and XAI are already being used for scientific queries, though verification of references produced by these models is crucial.

The Impact of GLP-1 Medicines

• 🚀 GLP-1 medicines, originating in the gut, regulate appetite, metabolism, and multiple organ systems, with Lilly's story in this area spanning decades.
• ✨ These drugs have evolved from early peptides to multi-mechanism molecules like tirzepatide, offering significant weight loss and broader health benefits.
• 📈 They can reduce caloric intake by approximately 800 calories per day and rapidly suppress inflammatory markers, leading to improvements beyond weight.
• 💖 The GLP-1 footprint is broadening, with trials showing benefits in cardiovascular metrics, liver and kidney disease, sleep apnea, psoriasis, chronic knee pain, Crohn's, and Alzheimer's prevention.

Overcoming Clinical Trial Challenges

• ⚠️ Clinical trials remain a major industry bottleneck, with late-stage trials costing $3-4 billion each and R&D accounting for roughly a quarter of sales.
• 💸 The average US clinical trial enrollment cost approaches $40,000 per participant, driving up both time and expense.
• 🛠️ Lilly is accelerating trials through proactive approaches like mining health records, direct-to-patient outreach, blood tests, televisits, and large-scale screening programs.

Reshaping Drug Distribution and Pricing

• 🛒 Lilly Direct allows patients to buy medicines online, bypassing intermediaries and easing access to prescriptions.
• 📊 Dave Ricks critiques opaque list prices, rebates, and middlemen for creating perverse incentives and distorting actual net prices.
• ✅ He proposes a **